Impel NeuroPharma To Present Data Highlighting Late-Stage Central Nervous System Pipeline At 2019 American Academy Of Neurology Meeting

Safety, Tolerability and Comparative Bioavailability Data Support INP104, Impel’s Nasal Drug Candidate for Acute Migraine

Results from the Company’s Phase 3 Clinical Program Evaluating INP104 for the Treatment of Acute Migraine Anticipated in Late 2019

Preclinical Data Support Selection of Company’s Novel Formulation of Nasal Levodopa, Currently Being Evaluated in Phase 2a Study in Parkinson’s Disease Patients During OFF Episodes CNS Marketing to Help Impel Evolve into a Fully-Integrated R&D and Commercial Organization

SEATTLE, April 30, 2019 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapeutics for patients suffering from central nervous system (CNS) disorders with high unmet medical needs, today announced that poster presentations highlighting its CNS pipeline, including preclinical, safety, tolerability and comparative bioavailability studies, will be presented at the upcoming American Academy of Neurology (AAN) annual meeting, to be held May 4 – 10, 2019 in Philadelphia, Pennsylvania.

“Impel is rapidly advancing our late-stage clinical programs in acute migraine, treatment of OFF episodes in Parkinson’s disease and acute agitation,” said Jon Congleton, Chief Executive Officer of Impel NeuroPharma. “We are excited to meet with members of the neurology community at AAN to discuss our clinical programs, such as dihydroergotamine (DHE) and levodopa (L-dopa), enabled by our proprietary upper nasal cavity drug delivery technology, which can support improved bioavailability with an easy-to-use, non-invasive approach.”

The meeting abstracts are available online and can be accessed via the below links or on the AAN meeting website at www.aan.com.

Poster Presentations:

Acute Migraine:

• P2.10-022: Precision Olfactory Delivery (POD®) of Drugs for Neurological Disease: A Safety, Tolerability and Comparative Bioavailability Study of POD Dihydroergotamine Mesylate (INP104) to Approved IV D.H.E. 45® and Migranal® Nasal Spray.
  Session: P2: Headache Clinical Trials II; 11:30 AM – 6:30 PM, Monday, May 6
• P2.10-017: Cardiovascular Profile of Dihydroergotamine Mesylate (DHE) Delivered by the POD® Device Compared to D.H.E. 45® for Injection from the INP104-101 Clinical Trial.
  Session: P2: Headache Clinical Trials II; 11:30 AM – 6:30 PM, Monday, May 6
• P4.9-056: A History of Dihydroergotamine in Migraine
  Session: P4: History of Neurology; 11:30 AM – 6:30 PM, Wednesday, May 8

Parkinson’s disease:

• P2.8-049: Preclinical Development of a Novel Precision Olfactory Delivery (POD®) – L-dopa Drug-Device Combination Product for the Treatment of OFF Episodes in Parkinson’s Disease
  Session: P2: Parkinson’s Disease Therapeutics I; 11:30 AM – 6:30 PM, Monday, May 6

The data that will be presented at the meeting support the ongoing “STOP-301 Trial” (Safety and Tolerability of POD-DHE), a Phase 3, open-label safety and tolerability study evaluating long-term, intermittent use of INP104 for the treatment of acute migraine, and the ongoing “THOR-201 Trial” (Therapeutic Benefit of Intranasal Levodopa in Parkinson’s Disease OFF Reversal), a Phase 2a study designed to explore the tolerability, pharmacokinetics and efficacy of INP103 and INP107 in Parkinson’s disease patients during an OFF episode compared to placebo.

Contact:

Melyssa Weible
Elixir Health Public Relations
Ph: (1) 201-723-5805
E: mweible@elixirhealthpr.com